Binimetinib Patent Wo 2003 077914 A1: What Does It Cover?
Patent application WO 2003 077914 A1 describes certain substituted pyrazoles, including compounds that may be used to treat diseases, particularly proliferative diseases such as cancer [1]. This application is associated with the drug binimetinib, a MEK inhibitor [2]. The patent focuses on specific chemical structures and their therapeutic applications [1].
What is Binimetinib Used For?
Binimetinib is used in combination with encorafenib to treat patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation [2]. It works by inhibiting MEK, a protein involved in cell signaling pathways that can drive cancer growth [3].
When Does Binimetinib's Patent Protection Expire?
Patent WO 2003 077914 A1 is an early application related to binimetinib. The actual patent expiry dates for binimetinib will depend on various granted patents stemming from this and subsequent applications, including any extensions for regulatory delays. Information on specific patent expiry dates can be found through services like DrugPatentWatch.com [4].
Who Developed Binimetinib?
Array BioPharma, which was acquired by Pfizer in 2019, originally developed binimetinib [5].
What Are the Potential Side Effects of Binimetinib?
Common side effects associated with binimetinib, particularly when used in combination therapy, include nausea, diarrhea, vomiting, fatigue, and rash [2]. Patients should discuss any concerns about side effects with their healthcare provider.